I Nazareth
Overview
Explore the profile of I Nazareth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1429
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beeken R, Leurent B, Vickerstaff V, Wilson R, Croker H, Morris S, et al.
Int J Obes (Lond)
. 2021 Jun;
45(9):2137-2138.
PMID: 34099843
No abstract available.
2.
Buylova Gola A, Morris S, Candy B, Davis S, King M, Kupeli N, et al.
Int Psychogeriatr
. 2020 Jan;
32(3):359-370.
PMID: 31948510
Objective: Nearly half of care home residents with advanced dementia have clinically significant agitation. Little is known about costs associated with these symptoms toward the end of life. We calculated...
3.
Fardet L, Nazareth I, Petersen I
Clin Epidemiol
. 2017 Nov;
9:545-554.
PMID: 29138600
Background: Hydroxychloroquine and chloroquine may reduce the risk of cancer as they inhibit autophagy, in particular, in people with connective tissue diseases. Methods: The hazard ratios of cancers, metastases, and...
4.
Blackburn R, Osborn D, Walters K, Nazareth I, Petersen I
Schizophr Res
. 2017 Jun;
192:219-225.
PMID: 28599749
Background: Severe mental illness (SMI) is associated with excess cardiovascular disease (CVD) morbidity, but little is known on provision of preventative interventions. We investigated statin initiation for primary CVD prevention...
5.
Blackburn R, Osborn D, Walters K, Falcaro M, Nazareth I, Petersen I
BMJ Open
. 2017 Mar;
7(3):e013154.
PMID: 28270387
Objectives: To estimate the 'real-world effectiveness of statins for primary prevention of cardiovascular disease (CVD) and for lipid modification in people with severe mental illnesses (SMI), including schizophrenia and bipolar...
6.
Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine
Osborn D, Marston L, Nazareth I, King M, Petersen I, Walters K
Schizophr Res
. 2016 Nov;
183:116-123.
PMID: 27884434
Method: We used data from The Health Improvement Network, a large UK primary care database to determine relative risks of (CVD) comparing similar groups of people only prescribed olanzapine versus...
7.
Beeken R, Leurent B, Vickerstaff V, Wilson R, Croker H, Morris S, et al.
Int J Obes (Lond)
. 2016 Nov;
41(2):246-254.
PMID: 27867204
Background: Primary care is the 'first port of call' for weight control advice, creating a need for simple, effective interventions that can be delivered without specialist skills. Ten Top Tips...
8.
Walters K, Hardoon S, Petersen I, Iliffe S, Omar R, Nazareth I, et al.
BMC Med
. 2016 Jan;
14:6.
PMID: 26797096
Background: Existing dementia risk scores require collection of additional data from patients, limiting their use in practice. Routinely collected healthcare data have the potential to assess dementia risk without the...
9.
Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis
Brueton V, Tierney J, Stenning S, Meredith S, Harding S, Nazareth I, et al.
BMJ Open
. 2014 Feb;
4(2):e003821.
PMID: 24496696
Objective: To quantify the effect of strategies to improve retention in randomised trials. Design: Systematic review and meta-analysis. Data Sources: Sources searched: MEDLINE, EMBASE, PsycINFO, DARE, CENTRAL, CINAHL, C2-SPECTR, ERIC,...
10.
Brueton V, Stevenson F, Vale C, Stenning S, Tierney J, Harding S, et al.
BMJ Open
. 2014 Jan;
4(1):e003835.
PMID: 24464427
Objective: To explore the strategies used to improve retention in primary care randomised trials. Design: Qualitative in-depth interviews and thematic analysis. Participants: 29 UK primary care chief and principal investigators,...